Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe

European Respiratory Journal

Volumn 49, Issue 6, 2017, Pages

  Van Der Werf, Marieke J ^a   Ködmön, Csaba ^a   Catchpole, Mike ^a  

^a EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; CLOFAZIMINE; ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE; AMIKACIN; KANAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; DIRECTLY OBSERVED THERAPY; DRUG RESISTANT TUBERCULOSIS; DRUG TREATMENT FAILURE; EUROPE; EVIDENCE BASED MEDICINE; HUMAN; LETTER; MEDICAL DECISION MAKING; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; SHORT COURSE THERAPY; TREATMENT DURATION; LUNG TUBERCULOSIS; PUBLIC HEALTH SERVICE; WORLD HEALTH ORGANIZATION;

EID: 85020201149     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00228-2017     Document Type: Letter

References (11)

1. van der Werf MJ, Hollo V, Ködmön C, et al. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union. Eur Respir J 2017; 49: 1601992.
2. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis-2016 update. Geneva, World Health Organization, 2016.
3. Falzon D, Schünemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017; 49: 1602308.
4. Yakrus MA, Driscoll J, McAlister A, et al. Molecular and growth-based drug susceptibility testing of Mycobacterium tuberculosis complex for ethambutol resistance in the United States. Tuberc Res Treat 2016; 2016: 3404860.
5. Rusch-Gerdes S, Domehl C, Nardi G, et al. Multicenter evaluation of the mycobacteria growth indicator tube for testing susceptibility of Mycobacterium tuberculosis to first-line drugs. J Clin Microbiol 1999; 37: 45-48.
6. Javaid A, Ahmad N, Khan AH, et al. Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country. Eur Respir J 2017; 49: 1601967.
7. Lange C, Duarte R, Frechet-Jachym M, et al. Limited benefit of the new shorter multidrug-resistant tuberculosis regimen in Europe. Am J Respir Crit Care Med 2016; 194: 1029-1031.
8. Varaine F, Guglielmetti L, Huerga H, et al. Eligibility for the shorter multidrug-resistant tuberculosis regimen: ambiguities in the World Health Organization recommendations. Am J Respir Crit Care Med 2016; 194: 1028-1029.
9. Sotgiu G, Tiberi S, D'Ambrosio L, et al. WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. Lancet 2016; 387: 2486-2487.
10. Sotgiu G, Tiberi S, D'Ambrosio L, et al. Faster for less: the new shorter regimen for multidrug-resistant tuberculosis. Eur Respir J 2016; 48: 1503-1507.
11. Dalcolmo M, Gayoso R, Sotgiu G, et al. Resistance profile of drugs composing the shorter regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015. Eur Respir J 2017; 49: 1602309.